View live charts, options flow & technicals for Insulet Corporation →
Open Dashboard
Insulet Corporation (PODD) is a healthcare company in the medical devices industry with $3.05B in trailing revenue trading at a 25.5× trailing P/E — analyst consensus: buy.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Key Statistics
Market Cap
$9.44B
Revenue (TTM)
$3.05B
EPS (TTM)
$5.34
EPS (Fwd est.)
$7.71
Employees
5,400
Trailing P/E
25.49
Forward P/E
17.66
PEG Ratio
1.07
Price / Sales
3.09
Price / Book
6.64
EV / EBITDA
16.03
Beta (5Y)
1.08
Analyst Consensus
Consensus
Buy
Analyst Price Target
+26.3% upside
Target: $171.91
Annual Revenue & Net Income
RevenueNet Income
'22
$1.31B
$0
'23
$1.70B
$210.00M
'24
$2.07B
$420.00M
'25
$2.71B
$250.00M
Earnings History
Quarter
Actual EPS
Estimate
Result
Aug 2026
$1.66
$1.45
Beat (+14.3%)
May 2026
$1.42
$1.19
Beat (+19.3%)
Feb 2026
$1.55
$1.46
Beat (+6.0%)
Nov 2025
$1.24
$1.15
Beat (+8.1%)
Next Earnings Report
Insulet Corporation is next expected to report earnings on 05 Nov 2026.
Profitability
71.1%
16.2%
12.3%
Gross MarginOperating MarginNet Margin
Revenue Growth (YoY)
23.5%
Return on Equity
26.0%
Return on Assets
9.7%
Balance Sheet
Cash & Equivalents
$530.00M
Total Debt
$950.00M
Net Position
$410.00M (net debt)
Free Cash Flow (TTM)
$240.00M
Debt / Equity
66.69
Share Ownership
Institutions 107.1%
Insiders 0.3%
Institutional figure exceeds 100% due to short selling
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain …
What is PODD's market cap?
Insulet Corporation has a market capitalization of approximately $9.44B.
What is PODD's P/E ratio?
Insulet Corporation trades at a trailing P/E ratio of 25.5x and a forward P/E of 17.7x, which is above the broad market average of ~25x.
How much revenue does PODD generate?
Insulet Corporation generated $3.05B in trailing 12-month revenue.
What do analysts say about PODD?
The analyst consensus rating for Insulet Corporation is buy, with a mean price target of $171.91. That implies +26.3% upside from the current price.
When does PODD report earnings?
Insulet Corporation is next scheduled to report earnings on 05 Nov 2026.
Does PODD pay a dividend?
Insulet Corporation does not currently pay a regular dividend.
View live charts, options flow, gamma exposure, earnings history, and technical analysis for Insulet Corporation on Apsis Markets.
